İdiyopatik Hipertrofik Pakimenenjit ve Ayırıcı Tanısı

Charcot JM, Joffroy A. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux anterolateraux de la moelle epiniere. Arch Physiol Norm Pathol. 1869;2: 354–67.

Naffzıger HC, Stern WE. Chronic pachymeningitis; report of a case and review of the literature. Arch Neurol Psychiatry. 1949;62(4):383-411.

Olmos PR, Falko JM, Rea GL, Boesel CP, Chakeres DW, McGhee DB. Fibrosing Pseudotumor of the Sella and Parasellar Area Producing Hypopituitarism and Multiple Cranial Nerve Palsies. Neurosurgery. 1993;32(6):1015-21.

Friedman D, Flanders A, Tartaglino L. Contrast-enhanced MR imaging of idiopathic hypertrophic craniospinal pachymeningitis. American Journal of Roentgenology. 1993;160(4):900-1.

Sharma V, Newton G, Wahal KM. Idiopathic hypertrophic pachymeningitis--an uncommon cause of cord compression. Indian J Pathol Microbiol. 1992;35(2):133-6.

De Kegel D, Vastmans J, Fehervary H, Depreitere B, Vander Sloten J, Famaey N. Biomechanical characterization of human dura mater. J Mech Behav Biomed Mater. 2018 Mar;79:122-34.

Dixon L, Lansley J, Hoskote J and Saada J. Skull and Brain. In Rafiee H (ed). Chapman & Nakielny's Aids to Radiological Differential Diagnosis, 7th ed. Philedelphia:Elsevier. 2020:13, 387-441.

Su J, Ren Q, Li P, et al. Clinical Observation of Various Types of Idiopathic Hypertrophic Cranial Pachymeningitis. World Neurosurg. 2024;181:e493-e503.

Kupersmith MJ, Martin V, Heller G, Shah A, Mitnick HJ. Idiopathic hypertrophic pachymeningitis. Neurology. 2004;62(5):686-94.

Botella C, Orozco M, Navarro J, Riesgo P. Idiopathic chronic hypertrophic craniocervical pachymeningitis: case report. Neurosurgery. 1994;35(6):1144-9.

Yonekawa T, Murai H, Utsuki S, et al. A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry. 2014;85(7):732-9.

Nicho N, Nozawa T, Murase A, et al. Difficulties of diagnosing idiopathic hypertrophic pachymeningitis in children: Case report and literature review. Mod Rheumatol Case Rep. 2023;7(1):233-6.

Riku S, Kato S. Idiopathic hypertrophic pachymeningitis. Neuropathology. 2003;23(4):335–44.

Yu H, Lu C, Duan W, et al. A selected case series of idiopathic hypertrophic pachymeningitis in a single center: Pathological characteristics and case-oriented review. J Neuroimmunol. 2023;383:578191.

Ashkenazi E, Constantini S, Pappo O, et al. Hypertrophic spinal pachymeningitis: report of two cases and review of the literature. Neurosurgery. 1991;28(5):730–2

Chan SK, Cheuk W, Chan KT, Chan JKC. IgG4-related Sclerosing Pachymeningitis. American Journal of Surgical Pathology. 2009;33(8):1249-52.

Melenotte C, Seguier J, Ebbo M, et al. Clinical presentation, treatment and outcome of IgG4-related pachymeningitis: From a national case registry and literature review. Semin Arthritis Rheum. 2019;49(3):430-7.

Hamano H, Kawa S, Horiuchi A, et al. High Serum IgG4 Concentrations in Patients with Sclerosing Pancreatitis. New England Journal of Medicine. 2001;344(10):732-8.

Lu LX, Della-Torre E, Stone JH, Clark SW. IgG4-Related Hypertrophic Pachymeningitis. JAMA Neurol. 2014;71(6):785.

Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. Journal of Allergy and Clinical Immunology. 2014;134(3):679-87.

Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. The Lancet. 2015;385(9976):1460-71.

Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4‐Related Disease. Arthritis & Rheumatology. 2020;72(1):7-19.

Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Modern Pathology. 2012;25(9):1181-92.

Masson C, Hénin D, Hauw JJ, Rey A, Raverdy P, Masson M. Cranial pachymeningitis of unknown origin. Neurology. 1993;43(7):1329.

Mamelak AN, Kelly WM, Davis RL, Rosenblum ML. Idiopathic hypertrophic cranial pachymeningitis. J Neurosurg. 1993;79(2):270-6.

Michel D, Girard PF, Tommasi M, Masson R, Trillet M, Piccinali JP. [Intracranial granulomatous pachymeningitis with pseudotumoral symptomatology. Apropos of 4 cases]. J Med Lyon. 1969;50(162):545-8.

Saito T, Fujimori J, Yoshida S, Kaneko K, Kodera T. Case of cerebral venous thrombosis caused by MPO-ANCA associated hypertrophic pachymeningitis. Rinsho Shinkeigaku. 2014;54(10):827-830. doi:10.5692/clinicalneurol.54.827

Lam BL, Barrett DA, Glaser JS, Schatz NJ, Brown HH. Visual loss from idiopathic intracranial pachymeningitis. Neurology. 1994;44(4):694.

Nemzek W, Postma G, Poirier V, Hecht S. MR features of pachymeningitis presenting with sixth-nerve palsy secondary to sphenoid sinusitis. AJNR Am J Neuroradiol. 1995;16(4 Suppl):960-3.

Choi IS, Park SC, Jung YK, Lee SS. Combined Therapy of Corticosteroid and Azathioprine in Hypertrophic Cranial Pachymeningitis. Eur Neurol. 2000;44(4):193-8.

Nakazakı H, Tanaka T, Isoshima A, Hida T, Nakajima M, Abe T. Idiopathic Hypertrophic Cranial Pachymeningitis With Perifocal Brain Edema. Case Report. Neurol Med Chir (Tokyo). 2000;40(4):239-43.

Shımatsu A, Oki Y, Fujisawa I, Sano T. Pituitary and Stalk Lesions (Infundibulo-hypophysitis) Associated with Immunoglobulin G4-related Systemic Disease: an Emerging Clinical Entity. Endocr J. 2009;56(9):1033-41.

Tsuchida K, Fukumura S, Yamamoto A, Akiyama Y, Hirano H, Tsutsumi H. Rapidly progressive fatal idiopathic hypertrophic pachymeningitis with brainstem involvement in a child. Child’s Nervous System. 2018;34(9):1795-98.

Digman KE, Partington CR, Graves VB. MR Imaging of Spinal Pachymeningitis. J Comput Assist Tomogr. 1990;14(6):988-90.

Bernat JL, Sadowsky CH, Vincent FM, Nordgren RE, Margolis G. Sclerosing spinal pachymeningitis. A complication of intrathecal administration of Depo-Medrol for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1976;39(11):1124-8.

Abrantes FF, Moraes MPM de, Rezende Filho FM, Pedroso JL, Barsottini OGP. A clinical approach to hypertrophic pachymeningitis. Arq Neuropsiquiatr. 2020;78(12):797-804.

Yao Y, Xu Y, Li X, et al. Clinical, imaging features and treatment response of idiopathic hypertrophic pachymeningitis. Mult Scler Relat Disord. 2022;66:104026.

Senda M, Ueda A, Ito M, et al. Long-term response to immunotherapy in patients with hypertrophic pachymeningitis. Fujita medical journal. 2023;9(1):35-40.

Hosler MR, Turbin RE, Cho ES, Wolansky LJ, Frohman LP. Idiopathic Hypertrophic Pachymeningitis Mimicking Lymphoplasmacyte-Rich Meningioma. Journal of Neuro-Ophthalmology. 2007;27(2):95-8.

Deprez M, Born J, Hauwaert C, Otto B, Reznik M. Idiopathic hypertrophic cranial pachymeningitis mimicking multiple meningiomas: case report and review of the literature. Acta Neuropathol. 1997;94(4):385-9.

Roche JC, Sánchez-Carteyron A, Mincholé E, Ara JR, Alarcia R. Reply: Idiopathic hypertrophic pachymeningitis mimicking neurosarcoidosis. Clin Neurol Neurosurg. 2012;114(6):825-6.

Ishiyama K, Okada M, Anzai N, Tashima M. Mantle cell lymphoma manifesting neurological symptoms similar to those of hypertrophic cranial pachymeningitis. Rinsho Ketsueki. 2011;52(11):1788-93.

Park IS, Kim H, Chung EY, Cho KW. Idiopathic Hypertrophic Cranial Pachymeningitis Misdiagnosed as Acute Subtentorial Hematoma. J Korean Neurosurg Soc. 2010;48(2):181.

Norikane T, Yamamoto Y, Okada M, et al. Hypertrophic Cranial Pachymeningitis With IgG4-Positive Plasma Cells Detected by C-11 Methionine PET. Clin Nucl Med. 2012;37(1):108-9.

Kioumehr F, Dadsetan MR, Feldman N, et al. Postcontrast MRI of cranial meninges: leptomeningitis versus pachymeningitis. J Comput Assist Tomogr. 1995;19(5):713-20.

Rojana-udomsart A, Pulkes T, Viranuwatti K, Laothamatas J, Phudhichareonrat S, Witoonpanich R. Idiopathic hypertrophic cranial pachymeningitis. J Clin Neurosci. 2008;15(4):465–9.

Ruiz-Sandoval JL, Bernard-Medina G, Ramos-Gomez EJ, et al. Idiopathic hypertrophic cranial pachymeningitis successfully treated with weekly subcutaneous methotrexate. Acta Neurochir. 2006;148(9):1011–4.

Assiotis A, Hadjivassiliou M. Idiopathic hypertrophic pachymeningitis responsive to mycophenolate. Acta Neurol Belg. 2011;111(3):252–4.

Popkirov S, Kowalski T, Schlegel U, Skodda S. Immunoglobulin-G4-related hypertrophic pachymeningitis with antineutrophil cytoplasmatic antibodies effectively treated with rituximab. Journal of Clinical Neuroscience. 2015;22(6):1038-1040.

Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease. Arthritis & Rheumatology. 2015;67(7):1688-99.

Jang Y, Lee ST, Jung KH, Chu K, Lee SK. Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis. Journal of Clinical Neurology. 2017;13(2):155.

Hatano N, Behari S, Nagatani T, et al. Idiopathic hypertrophic cranial pachymeningitis: clinicoradiological spectrum and therapeutic options. Neurosurgery. 1999;45(6):1336-44.

Khalid A, Uche EO. Idiopathic Hypertrophic Cranial Pachymeningitis With Chiari Type I Malformation: Case Report and Review of the Literature. Cureus. 2022;14(8):e28466.